Artemisinin has a potent and rapid killing effect on all types of Plasmodium vivax. It is suitable for the treatment of all types of malaria, especially for chloroquine-resistant severe falciparum malaria and cerebral malaria. Artemisinin is more potent than both quinine and chloroquine, and has no cross-resistance to chloroquine. However, its mechanism has not been fully understood; it is known that it may interfere with the structure of the Plasmodium membrane system, inhibit the function of the surface membrane and mitochondria, and block the uptake of hemoglobin by Plasmodium, leading to the collapse of the membrane system and death. Artemisinin is easily tolerated. There are only mild adverse effects such as gastrointestinal discomfort, nausea, vomiting, diarrhea, dizziness, tinnitus, neutropenia, and elevated serum transaminases. Artemisinin is embryotoxic and should be used with caution in pregnant women, especially in the first 3 months of pregnancy. It has not been clarified whether this product can be secreted through breast milk, nursing women should suspend breastfeeding when using. This product should be used in accordance with medical advice.